Delorme J. auteur aut IRD Paraponaris A. auteur aut IRD Moatti Jean-Paul auteur aut IRD text journalArticle eng This article gives empirical evidence for the bargaining process between pharmaceutical firms and hospital buyers in the field of anticancer drugs. Transactions prices and quantities have been collected over the whole population of 40 hospitals and clinics that, in southeastern France, provided anticancer care from 1997 to 2000. Hospital transaction prices are very sensitive to the payment system : prices paid by not-for-profit hospitals for a chemotherapy course are 7.4% cheaper than prices paid by private for-profit hospital. Generic competition has substantial negative effect on price : 72% when a drug faces a generic competitor. specialized FRANCE 050 16 4 87-104 2008 1538-5698 https://www.documentation.ird.fr/hor/PAR00004973 10.1080/15385690801963613 1538-5698 https://www.documentation.ird.fr/hor/PAR00004973 IRD - Base Horizon / Pleins textes 2010-05-06 2017-08-23 PAR00004973 fre